Hepatitis C Antiviral Treatment (DAA) — free guideline decision tool
This tool gives the HCV direct-acting-antiviral regimen direction by cirrhosis status and pregnancy, with pre-treatment assessment and the SVR12 endpoint.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Common questions
What does Hepatitis C Antiviral Treatment (DAA) do?
Use to choose a pangenotypic regimen in non-cirrhotic/compensated disease, a specialist SOF/VEL + RBV regimen in decompensation, and to defer therapy in pregnancy.
How is the result calculated?
No cirrhosis/compensated → SOF/VEL 12 weeks or GLE/PIB 8 weeks. Decompensated → protease inhibitors contraindicated, SOF/VEL + RBV 12 weeks. Pregnant → defer. Endpoint SVR12.
Is this a substitute for clinical judgement?
No. All results are decision-support only, for licensed clinicians. They must be individualized to the whole patient and the latest guideline version.
Run Hepatitis C Antiviral Treatment (DAA) now
This tool gives the HCV direct-acting-antiviral regimen direction by cirrhosis status and pregnancy, with pre-treatment assessment and the SVR12 endpoint.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.